Credit Suisse Upgrades ResMed (RMD) to Outperform
RMD Hot Sheet
Rating Summary:4 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Credit Suisse upgrades ResMed (NYSE: RMD) from Neutral to Outperform.
To see more analyst ratings on RMD Click Here.
ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
To see more analyst ratings on RMD Click Here.
ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Macquarie Upgrades SBA Communications (SBAC) to Outperform
- UBS Maintains a 'Neutral' on VeriFone (PAY); Europe Demand Healthy, but FX Emerges as Headwind
Create E-mail Alert Related Categories
UpgradesRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
